Characteristics and treatment regimens across ERS SHARP severe asthma registries

6533b7d7fe1ef96bd126848d

RESEARCH PRODUCT

Characteristics and treatment regimens across ERS SHARP severe asthma registries

Jjmh Van Bragt Im Adcock Ehd Bel Gj Braunstahl A Ten Brinke J Busby Gw Canonica H Cao Kf Chung Z Csoma B Dahlen E Davin S Hansen E Heffler I Horvath S Korn M Kots P Kuna N Kwon R Louis V Plaza C Porsbjerg D Ramos-barbon Lb Richards S Skrgat Jk Sont Sjh Vijverberg Ejm Weersink V Yasinska Ss Wagers R Djukanovic Ah Maitland-van Der Zee B Abenhardt Im Adcock J Adler R Alfonso R Ali S Alkameh Ca Sanchez L Alvares G Anderson K Assing S Ayre J Becker Ehd Bel K Bergmann K Bieksiene N Bjerring F Blasi P Bloemen H Blum S Boing M Bonavia A Bossios A Bourdin Gj Braunstahl A Brons G Brusselle J Buis J Busby M Caiaffa C Calabrese G Camiciottoli Gw Canonica H Cao C Caruso Mc Martinez S Centanni Kf Chung Cc Serrano A Corsico L Cosmi M Costantino R Costello N Crimi Z Csoma S Dahlen B Dahlen M D'amato D Davies E Davin Fdgc Piqueras G Decarlo A Deimling S Del Giacco Rd Campos M Djandji R Djukanovic D Doberer L Dupont K Dyett N Edelbaher M Edelmann R Ehmann A Ekberg-jansson A Farsi E Favero J Feimer M Fletcher B Foschino B Frankemolle M Gaga M Gappa Jg De Pedro Jg Rivero M Gasplmayr R Gebhardt H Geldmacher C Geltner M Gerstlauer T Gibson G Giuseppe C Gogoll V Grimm-sachs I Grisle B Grun A Grunewaldt G Guarnieri Jg Blanco E Hamelmann D Hamerlijnck A Hammers-reinhard S Hanon S Hansen D Harzheim L Heaney E Heffler S Hellmich M Herden T Hering F Herth O Hilberg I Horvath P Howarth M Hubatsch M Humbert K Husemann M Idzko D Jackson M Jandl X Jaumont G Joos M Jost M Juch M Kabesch P Kaiser-labusch P Kardos F Kassner T Keeley W Kerr J Kirschner L Klimek M Koca R Koczulla C Koerner-rettberg P Kopac S Korn M Kots J Kronsbein P Kuna Ik Lipinska N Kwon M Langer B Langeveld A Lantz N Lazarinis Z Lazic L Lehtimaki J Leuppi C Lombardi M Lommatzsch A Lopez-vina R Louis R Luca D Ludviksdottir C Luttecke-hecht L Macchia T Magni Ah Maitland-van Der Zee Cm Rivera P Mastoridis F Mazza F Menzella A Menzies-gow A Michils F Mihaltan M Milanese K Milger-kneidinger J Molinska I Montagna P Montuschi N Mulleneisen Mm Esquerre A Nanzer-kelly N Nenasheva C Neurohr E Nucera J Otker K Oud P Paggiaro R Parente J Parkinson G Passalacqua N Patberg V Patella O Patino T Paulsson R Peche G Pelaia E Peress Lp De Llano P Pfeffer P Pfister C Pilette Cp Sierra L Pini V Plaza C Porsbjerg F Powitz D Ramos-barbon T Ranger L Rasmussen K Rasmussen M Rezelj L Ricciardi F Ricciardolo Lb Richards E Ridolo L Rijssenbeek-nouwens G Rolla Dr Ribate S Rudiger G Safioti T Sandstrom P Santus R Sauer G Schauerte R Schipmann F Schleich J Schmid F Schmidt O Schmidt M Schmitz T Schrag S Schroer K Schultz C Schulz N Scichilone V Sedlak J Selb G Senna S Sergejeva Js Pariente M Sichau D Simona A Singer D Skowasch S Skrgat F Smeenk S Smith P Solidoro Jk Sont G Spadaro A Spanevello M Stefansdottir K Steinmetz J Steiss M Stephan S Stieglitz H Suhling C Taube A Ten Brinke St Yavuz N Tudoric C Ulrik Jjmh Van Bragt M Van De Ven F Van Den Elshout M Van Dyke S Van Nederveen-bendien I Van Veen O Vandenplas K Velthove A Vianello Sjh Vijverberg C Vogelberg Ss Wagers E Wallen-nielsen Ej Weersink T Wisskirchen M Yacoub S Yancey V Yasinska M Zappa S Zielen C Zimmermann R Zimmermann

subject

Severe asthma Pediatrics MESH: Registries MESH: Asthma Cross-sectional study Respiratory System Medizin [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract 0302 clinical medicine MESH: Belgium Belgium Medicine research Anti-Asthmatic Agents Registries 030212 general & internal medicine [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology 10. No inequality 11 Medical and Health Sciences Netherlands 2. Zero hunger education.field_of_study SHARP CRC MESH: Administration Inhalation MESH: Anti-Asthmatic Agents 3. Good health Europe Italy MESH: Poland MESH: Sweden medicine.drug Pulmonary and Respiratory Medicine medicine.medical_specialty MESH: Hungary Population Investigació mèdica Settore MED/10 - Malattie Dell'Apparato Respiratorio 03 medical and health sciences MESH: Cross-Sectional Studies Administration Inhalation MESH: Spain medicine Humans education Asma Retrospective Studies Asthma Sweden Hungary MESH: Humans business.industry Settore MED/09 - MEDICINA INTERNA MESH: Italy MESH: Retrospective Studies Retrospective cohort study Original Articles asthma medicine.disease Asthma Clinical trial Cross-Sectional Studies Clinical research 030228 respiratory system Spain MESH: Netherlands MESH: Europe Poland business Body mass index Mepolizumab

description

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.

year	journal	country	edition	language
2020-01-09	European Respiratory Journal

https://doi.org/10.1183/13993003.01163-2019